|
|
|
This is the preliminary program for the 2009 Joint Statistical
Meetings in Washington, DC.
|
|
|
The views expressed here are those of the individual authors and not necessarily those of the ASA or its board, officers, or staff. Back to main JSM 2009 Program page |
= Applied Session,
= Theme Session,
= Presenter
325
|
Tue, 8/4/09, 10:30 AM - 12:20 PM | CC-204A |
| Issues in Subgrouping Analysis and Preclinical and Phase I Trials - Contributed - Papers | ||
|
Biopharmaceutical Section |
||
| Chair(s): Jonathan Norton, FDA | ||
| 10:35 AM |
Dose-Response Assay Equivalence with Replicate Data —  Steven Novick, GlaxoSmithKline
|
|
| 10:50 AM |
Subgroup Heterogeneity in Drug Efficacy — Qiang (Casey) Xu, FDA; Rajeshwari Sridhara, FDA; Shenghui Tang, FDA; Yu-Ling Chang, FDA
|
|
| 11:05 AM |
Fit Five-Parameter Logistic Function for Assay Data Using SAS — Rong Liu, Merck & Co., Inc.; Shuping Zhang, Merck & Co., Inc.; Jason Liao, Merck Research Laboratories; Shuping Zhang, Merck & Co., Inc.
|
|
| 11:20 AM |
A Clinically More Meaningful Interaction Test of Treatment Effects Within Subgroups — Weihua Tang, Bristol-Myers Squibb Company; David H. Henry, Bristol-Myers Squibb Company; Lisa Ying, Bristol-Myers Squibb Company
|
|
| 11:35 AM |
Rationale for Sponsor-Unblinded Phase I Trials: Challenging the Double-Blind Paradigm — Jitendra Ganju, Amgen, Inc.; Clapton Dias, Amgen, Inc.
|
|
| 11:50 AM |
Dose-Time-Effect Modeling for Cancer Cell Growth in In-Vitro Experiments — Maiying Kong, University of Louisville
|
|
| 12:05 PM |
Understanding the Key Factors in the Design of a Randomized Thorough QT Study — Jessie Qing Xia, National Institute of Statistical Sciences; Alexei A. Dmitrienko, Eli Lilly and Company; Beasley Charles, Eli Lilly and Company; S. Stanley Young, National Institute of Statistical Sciences
|
|
|
JSM 2009
For information, contact jsm@amstat.org
or phone (888) 231-3473. If you have questions about the Continuing Education program,
please contact the Education Department. |